Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▲ +0.6% | ▼ −2.2% | ▲ +9.2% | — | — | — | — | ▲ +36.0% |
| Peer average | ▼ −2.3% | ▼ −15.2% | ▼ −2.7% | ▲ +1.0% | ▼ −3.1% | ▲ +113.6% | ▲ +60.5% | — |
| S&P 500 · VOO | ▼ −0.4% | ▲ +0.9% | ▲ +3.3% | ▲ +13.8% | ▲ +13.3% | ▲ +88.8% | ▲ +81.9% | — |
Reported holdings are shown below. A share-of-fund chart is unavailable for this portfolio.
Holdings as of 2026-10-30. Derivatives are shown using their reported instrument names.
| Holding | Instrument | Weight |
|---|---|---|
| STATE STREET SPDR S&P BIOTECH ETF-SWAP-CANT-L | swap | 199.14% |
| Cash & Other | Reported holding | -99.14% |
Official documents are being connected from SEC EDGAR. Read the issuer’s prospectus before investing.
XBIX seeks to deliver 200% of the daily performance of SPDR S&P Biotech ETF (Ticker: XBI), a passively managed ETF with a targeted exposure to US biotechnology stocks. Rather than holding XBI directly, the fund primarily uses derivatives such as swap agreements and options to create leveraged exposure. The portfolio is rebalanced at the end of each trading day to maintain its targeted leverage level, meaning returns over periods longer than a single day can differ significantly from two times the cumulative return of XBI due to compounding effects. The fund may also obtain leveraged exposure through exchange-traded equity futures contracts and exchange-traded options contracts, including standardized call and put options. Collateral supporting these derivative positions may be invested in money market instruments, repurchase agreements, or short-term US government securities.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
Verified payout history is unavailable.
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind XBIX.